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Abstract 19 
A multifactorial [temperature (40, 50 and 60°C), hydrolysis time (60, 150 and 240 min) and 20 
enzyme to substrate ratio (E:S; 1.0, 1.5 and 2.0%)] design of experiments (DOE) was used to 21 
optimise the release of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides during 22 
hydrolysis of bovine milk protein isolate (MPI) with Neutrase 0.8L
TM
, yielding 15 23 
hydrolysates (H1-H15). Variation in temperature and time had a significant effect on DPP-IV 24 
inhibitory properties (p < 0.05) in contrast with E:S (p > 0.05). The DPP-IV half maximal 25 
inhibitory concentration (IC50) of H4, a potent sample, was maintained following simulated 26 
gastrointestinal digestion (SGID, DPP-IV IC50 = 0.60 ± 0.06 vs. 0.58 ± 0.09 mg mL
-1
, p > 27 
0.05). Several peptides with DPP-IV inhibitory features or known activity were identified by 28 
liquid chromatography-tandem mass spectrometry (LC-MS/MS) within the hydrolysates. 29 
MPI hydrolysates may have potential for use as dietary ingredients with serum glucose 30 
lowering activity in humans. 31 
 32 
 33 
Key words: dipeptidyl peptidase IV inhibition; milk protein isolate; bioactive peptides; 34 
response surface methodology. 35 
36 
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1 Introduction 37 
Milk proteins contain within their sequences encrypted peptides, known as bioactive 38 
peptides, which may have potential to contribute to a wide range of bioactive properties in 39 
vitro. While there is still much debate around the application of bioactive peptides to 40 
modulate human health, there is a growing evidence in the literature reporting on their 41 
positive outcomes during human intervention studies (Nongonierma & FitzGerald, 2015a). 42 
The role of milk protein-derived peptides as antidiabetic agents has attracted a lot of interest. 43 
In particular, the inhibition of dipeptidyl peptidase IV (DPP-IV), a metabolic enzyme, with 44 
various food protein-derived peptides has been extensively studied (Lacroix & Li-Chan, 45 
2016). During the postprandial phase, DPP-IV is able to cleave incretins such as glucagon-46 
like peptide 1 (GLP-1) and glucose inhibitory polypeptide (GIP). Incretin cleavage results in 47 
their inactivation, which causes a loss in their insulinotropic activity (Juillerat-Jeanneret, 48 
2014). Several DPP-IV inhibitory drugs, which belong to the class gliptins, are currently used 49 
by type 2 diabetics as a means to regulate of postprandial serum glucose. While being 50 
reported as minor, a number of side-effects, have been associated with the utilisation of 51 
gliptins (Zhao et al., 2016). In this context, the search for natural dietary compounds, which 52 
are not linked to any adverse side-effects (Eckert et al., 2014; Zambrowicz et al., 2015), may 53 
be of interest. 54 
The potency of most food protein-derived DPP-IV inhibitory peptides identified in the 55 
literature is generally 1000 times less than that of gliptins (Nongonierma & FitzGerald, 56 
2013b). Currently, the most potent DPP-IV inhibitory peptide identified within food proteins 57 
is Ile-Pro-Ile (Diprotin A), which is present in dietary proteins such as κ-casein (CN) or 58 
chicken egg ovotransferrin. Identification of more potent peptides is of interest to develop 59 
dietary ingredients having antidiabetic effects in humans. The optimisation of bioactive 60 
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peptide release during enzymatic hydrolysis of milk proteins has been described using 61 
multifactorial design of experiments (DOE) and response surface methodology (RSM) 62 
approaches (van der Ven, Gruppen, de Bont & Voragen, 2002). More recently, these 63 
approaches have been described to optimise the release of DPP-IV inhibitory peptides during 64 
the hydrolysis of MPI with trypsin (Nongonierma, Mazzocchi, Paolella & FitzGerald, 2017). 65 
It was shown that alteration of hydrolysis parameters (i.e., time and temperature) could 66 
influence the DPP-IV inhibitory potency of the resultant MPI hydrolysates. The application 67 
of DOE and RSM could therefore be used to aid in the development of more potent DPP-IV 68 
inhibitory hydrolysates. 69 
Several milk protein-derived hydrolysates/peptides have been reported for their ability to 70 
inhibit DPP-IV in vitro and also in small animals. The generation of milk protein-derived 71 
hydrolysates has mainly been achieved using either individual milk proteins or whey and CN-72 
dominant substrates. These substrates lead to the generation of relatively potent DPP-IV 73 
inhibitory hydrolysates/peptides (Lacroix & Li-Chan, 2016). However, little is known in 74 
terms of the potency of hydrolysates arising from the concomitant hydrolysis of whey 75 
proteins and CNs. Milk protein isolate (MPI) is a commercially available low-lactose and 76 
low-fat protein-rich substrate (~90% (w/w) protein) containing CNs and whey proteins in the 77 
same ratio as they exist in bovine milk (Agarwal, Beausire, Patel & Patel, 2015). MPI has 78 
mainly been reported for its technofunctional properties (texturising, foaming, heat stability, 79 
gelation, water binding capacity, etc.) (Agarwal et al., 2015). MPI hydrolysates have been 80 
used for the generation of antioxidant (Hogan, Zhang, Li, Wang & Zhou, 2009) and DPP-IV 81 
inhibitory peptides (Nongonierma et al., 2017). Overall, bioactive peptide generation during 82 
enzymatic hydrolysis of MPI appears to have been underreported. 83 
The aim of this study was to evaluate the potential of MPI to act as a source of DPP-IV 84 
inhibitory peptides. A DOE (three levels and three factors, i.e., temperature, time and enzyme 85 
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to substrate (E:S) ratio) followed by RSM was employed to optimise DPP-IV inhibitory 86 
peptide release during Neutrase 0.8L
TM
 hydrolysis of MPI. In addition, the physicochemical 87 
characteristics (degree of hydrolysis (DH), peptide profile and molecular mass distribution) 88 
of the MPI hydrolysates were determined. The stability of the DPP-IV inhibitory properties 89 
of MPI hydrolysates following incubation with digestive enzymes was assessed using an in 90 
vitro simulated gastrointestinal digestion (SGID) protocol. Finally peptide identification of 91 
selected MPI hydrolysates was determined by liquid chromatography-tandem mass 92 
spectrometry (LC-MS/MS). 93 
2 Materials and methods 94 
2.1 Reagents 95 
2,4,6-Trinitrobenzenesulfonic acid (TNBS) from Pierce Biotechnology was obtained from 96 
Medical Supply Company (Dublin, Ireland). Hydrochloric acid (HCl), sodium hydroxide 97 
(NaOH), high performance liquid chromatography (HPLC) grade water and acetonitrile were 98 
from VWR (Dublin, Ireland). Trifluoroacetic acid (TFA), tris(hydroxymethyl)aminomethane 99 
(TRIS), sodium phosphate monobasic, sodium phosphate dibasic, sodium dodecyl sulphate 100 
(SDS), Gly-Pro-pNA, Leu, diprotin A (Ile-Pro-Ile), porcine DPP-IV (≥ 10 units mg-1 protein), 101 
standards for molecular mass distribution (i.e., bovine serum albumin (BSA), β-lactoglobulin 102 
(β-Lg), -lactalbumin (-La), aprotinin, bacitracin, Leu-Trp-Met-Arg, Asp-Glu and Tyr), 103 
mass spectrometry (MS) grade water and acetonitrile were purchased from Sigma Aldrich 104 
(Dublin, Ireland). Synthetic peptides used for MS confirmatory studies were purchased from 105 
Sigma-Aldrich (His-Leu and Phe-Leu), Genscript (Piscataway, NJ, USA; Phe-Phe), Bachem 106 
(Bubendorf, Switzerland; Trp-Lys and Val-Leu) and Thermo Fisher Scientific (Ulm, 107 
Germany; Ile-Ile Ile-Leu, Leu-Ile, Leu-Leu and Trp-Gln). Milk protein isolate (MPI, 86% 108 
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(w/w) protein) was obtained from Kerry Ingredients (Listowel, Ireland). Neutrase 0.8L
TM
 was 109 
provided by Novozymes (Bagsvaerd, Denmark).  110 
2.2 Hydrolysis of MPI 111 
Hydrolysis of MPI was carried out with Neutrase 0.8L
TM
 using a multifactorial design 112 
essentially as already outlined in Nongonierma et al. (2017). Each factor including the 113 
incubation temperature (T; 40, 50 and 60°C), incubation time (t; 60, 150 and 240 min), and 114 
the enzyme: substrate ratio (E:S; 1.0, 1.5 and 2.0% (v/w)) were evaluated at three (-1, 0 and 115 
+1, respectively) different levels (Table 1). Each condition of the DOE was used once for 116 
hydrolysate generation, with the exception of the central point (50C, 150 min and 1.5% 117 
E:S), which was generated in triplicate (H8A, H8B and H8C). Fifteen different hydrolysates 118 
(H1-H15) were generated. 119 
The RSM (see section 2.8) allowed prediction of the optimum hydrolysis parameters for 120 
DPP-IV inhibition by the MPI hydrolysates. These predicted optimum hydrolysis conditions 121 
were then used for the triplicate generation of an MPI hydrolysate (H16A, H16B and H16C). 122 
MPI was resuspended (10% (w protein equivalent/w)) in distilled water for 60 min in a water 123 
bath (Lauda E100, Lauda Brinkmann, Lauda-Königshofen, Germany) set at 50C. The pH of 124 
the MPI solution was subsequently adjusted to 7.0 with 2 M NaOH. The MPI solution was 125 
then equilibrated at the desired incubation temperature and Neutrase 0.8L
TM
 was 126 
subsequently added at the desired E:S ratio as defined in the DOE. When the target 127 
incubation time was reached, the enzyme was heat inactivated in a water bath set at 90°C for 128 
20 min. Unhydrolysed MPI was used as a control sample which was incubated using the 129 
same temperature and time conditions as the hydrolysates but without enzyme addition. All 130 
samples (hydrolysates and controls) were freeze-dried (FreeZone 18L, Labconco, Kansas 131 
City, MO, USA) and stored at -20°C prior to further analysis. 132 
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2.3 In vitro SGID of intact and hydrolysed MPI 133 
Both unhydrolysed MPI and H4 (one of the most potent DPP-IV inhibitory hydrolysate 134 
generated within the experimental design) were subjected to SGID in vitro. This was carried 135 
out as described by Walsh et al. (2004). Briefly, samples were resuspended in distilled water 136 
to 2% (w protein equivalent/w) for 30 min at 37°C and the pH was adjusted to 2.0 using 1 N 137 
HCl. Hydrolysis with pepsin (E:S 2.5% (w/w); Biocatalysts, Cefn Coed, Wales, UK) was 138 
carried out under pH regulation (2.0) with HCl (pH stat Titrando 843, Tiamo 1.4 Metrohm, 139 
Dublin, Ireland) for 90 min at 37°C. Pepsin was then heat inactivated (90°C, 20 min). An 140 
aliquot of the peptic hydrolysate (H4_pepsin or MPI_pepsin) was brought to pH 7.5 using 1 141 
M NaOH and was subsequently hydrolysed with Corolase PP (E:S 1% (w/w); AB Enzymes, 142 
Darmstadt, Germany) for 150 min at 37°C, pH 7.5 using a pH stat (Metrohm), yielding 143 
H4_CorPP or MPI_CorPP. The reaction was terminated by thermal treatment (90°C, 20 min). 144 
Samples were then freeze-dried and stored at -20°C until utilisation. 145 
2.4 Determination of the DH 146 
The DH of each hydrolysate (H1-H15) was determined in triplicate (n=3) using the TNBS 147 
method outlined in Le Maux, Nongonierma, Barre & FitzGerald (2016). Absorbance values 148 
at 350 nm were measured using a microplate reader (Biotek Synergy HT, Winoosky, VT, 149 
USA). The DH was calculated according to Equation 1: 150 
DH = 100 ×
(AN2−AN1)
N𝑝𝑏 
        Equation 1 151 
 152 
With AN1, the amino nitrogen content of the unhydrolysed protein (mg g
-1
 protein); AN2, the 153 
amino nitrogen content of the hydrolysate (mg g
-1
 protein) and Npb, the nitrogen content of 154 
the peptide bonds in the protein substrate (114.34 for MPI). 155 
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2.5 Determination of the molecular mass distribution of the hydrolysates by gel 156 
permeation (GP)-HPLC 157 
The MPI hydrolysates were analysed by GP-HPLC as described by Spellman, O’Cuinn & 158 
FitzGerald (2009) using a Waters (Milford, MA, USA) HPLC system (model 600 binary 159 
pump, model 2707 autosampler and model 2489 dual λ absorbance detector interfaced with 160 
Empower™). The mobile phase consisted of 0.1% (v/v) TFA and 30% HPLC grade 161 
acetonitrile in HPLC water. Samples were resuspended in the mobile phase at 0.22% (w 162 
protein equivalent/v) and filtered through 0.2 µm PTFE syringe filters (VWR). The 163 
separation was carried out in isocratic mode at 21°C by injecting 20 µL of sample into a TSK 164 
G2000 SW separating column (600×7.5 mm ID - Tosoh Bioscience, Tokyo, Japan) connected 165 
to a TSKGEL SW guard column (75×7.5 mm ID - Tosoh Bioscience). The flow rate was set 166 
at 0.5 mL min
-1
 for 60 min. The absorbance was monitored at 214 nm. Four molecular mass 167 
bands within the chromatograms were defined as > 10, 10-5, 5-1 and < 1 kDa. 168 
2.6 Peptide profiling of the hydrolysates using reverse-phase ultra-performance liquid 169 
chromatography (RP-UPLC) 170 
The peptide profile of the MPI hydrolysates was determined by RP-UPLC (UPLC Acquity - 171 
Waters) as per Nongonierma & FitzGerald (2012). Solvent A was 0.1% (v/v) TFA in MS 172 
grade water and solvent B was 0.1% (v/v) TFA and 80% MS grade acetonitrile in water. The 173 
samples were resuspended (0.4% w protein equivalent/v) in solvent A and filtered using 0.2 174 
µm cellulose acetate filters (VWR). Peptide separation was carried out by RP-UPLC at 30°C, 175 
flow rate of 0.3 mL min
-1
 and an injection volume of 10 µL. An Acquity UPLC BEH C18, 176 
130 Å column (2.1 mm  50 mm  1.7 µm) equipped with an Acquity BEH C18 (1.7 µm) 177 
vanguard pre-column, from Waters, was used. Peptides and proteins were eluted using a 178 
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linear gradient: 0-0.28 min: 100% A; 0.28-60 min: 100-40% A. Absorbance was monitored at 179 
214 nm. 180 
2.7 DPP-IV inhibition assay 181 
The DPP-IV inhibition assay was carried out as outlined by Nongonierma & FitzGerald 182 
(2013a). Briefly, the freeze-dried samples were dispersed in HPLC grade water at 183 
concentrations ranging from 2.7 × 10
-2
 to 2.7 mg mL
-1
 (final concentration expressed in mg 184 
protein equivalent mL
-1
). Diprotin A was used as a positive control at concentrations between 185 
12.5 × 10
-2
 and 12.5 µg mL
-1
. Samples (25L) were mixed with the reaction substrate, Gly-186 
Pro-pNA (final concentration 0.200 mM) in a 96-well clear microplate (Sarstedt, Dublin, 187 
Ireland). DPP-IV was subsequently added to a final concentration of 0.0025 units mL
-1
. The 188 
microplate was incubated at 37C for 60 min in a microplate reader (Biotek Synergy HT). 189 
Absorbance of the pNA released was monitored at 405 nm. The DPP-IV half maximal 190 
inhibitory concentration (IC50) values were determined by plotting the percentage inhibition 191 
as a function of test compound concentration. Each analysis was conducted in triplicate 192 
(n=3). 193 
2.8 RSM and generation of the optimum MPI hydrolysate 194 
A multilinear regression (MLR) model (Equation 2) was used to link the experimental design 195 
parameters (temperature, time and E:S) to the DPP-IV IC50 value of the hydrolysates using 196 
Matlab (version R2014b, MathWorks, Inc, Natick, MA, USA) as previously described 197 
(Nongonierma et al., 2017). 198 
 199 
Y = β0 + β1T + β2t + β3ES + β4𝑇
2 + β5𝑡
2 + β6𝐸𝑆
2 + β7Tt + β8T × ES + β9t × ES +  ε (Equation 200 
2) 201 
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 202 
With Y, the DPP-IV IC50 value; β0 to β9: the coefficients of the MLR model; T, t and ES: the 203 
centred and reduced (z-centred) parameters of the experimental design and ε: the residual of 204 
the model. 205 
The MLR (Equation 2, complete model) was further simplified (simplified model) by only 206 
taking into account the main parameters (T, t and ES) and their interactions having a p-value 207 
 0.2 (van der Ven et al., 2002). The simplified model was used to plot the RSM and to 208 
predict the optimum parameters yielding the lowest DPP-IV IC50 values within the 209 
experimental domain (van der Ven et al., 2002). 210 
2.9 LC-MS/MS analysis of MPI hydrolysates 211 
The peptide composition of one of the most potent DPP-IV inhibitory hydrolysate (H4) and 212 
its corresponding SGID sample was assessed by LC-MS/MS. This was carried out using an 213 
Acquity UPLC (Waters) fitted with an Acquity BEH amide 300 C18 RP column (2.150 mm, 214 
1.7 μm, Waters). The UPLC was coupled to a quadrupole time-of-flight mass spectrometer 215 
(Q-TOF, Impact HD™, Bruker Daltonics GmbH, Bremen, Germany) using a 50-600 and 50-216 
2500 m/z acquisition range as described earlier (Norris, Poyarkov, O’Keeffe & FitzGerald, 217 
2014; O’Keeffe & FitzGerald, 2015). The MS was fitted with an electrospray ionisation (ESI) 218 
source used in positive ion mode. Data acquisition was performed with Hystar software 219 
(Bruker Daltonics). Samples were resuspended in mobile phase A (0.1% formic acid in MS 220 
water) to a final concentration of 0.1 mg mL
-1
. A sample volume of 2 µL was injected into 221 
the column. Peptide identification was carried out with PEAKS Studio (version 7.5, 222 
Bioinformatics Solutions Inc, Waterloo, Canada) and its database search tools including 223 
PEAKS DE NOVO sequencing, PEAKS BD (database search), PEAKS PTM (post-224 
transitional modifications) and SPIDER (algorithm that matches sequence tags with errors to 225 
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database sequences for the purpose of protein and peptide identification). The database used 226 
was UniProtKB/Swiss-Prot (http://www.uniprot.org), taxa Bos taurus. The false discovery 227 
rate (FDR), average local confidence (ALC) and MS/MS tolerance were set at 1, 60% and 0.1 228 
Da, respectively. In addition, synthetic peptides (Phe-Phe, Phe-Leu, His-Leu, Leu-Leu, Ile-229 
Leu, Leu-Ile, Ile-Ile, Val-Leu, Trp-Lys and Trp-Gln) were analysed using the same LC-230 
MS/MS conditions in order to confirm the software identification (data not shown). All other 231 
amino acid sequences generated by PEAKS Studio software were manually checked in order 232 
to (1) verify that the peptide sequence existed in the main milk proteins and (2) control the 233 
peptides fragmentation data (i.e., ion series continuity). 234 
Previously identified DPP-IV inhibitory peptides were searched for in the hydrolysates (H4, 235 
H4_CorPP, MPI_CorPP and H16). In addition, features of known DPP-IV inhibitory peptides 236 
reported in the literature which consist of an hydrophobic amino acid (Trp, Leu, Ile or Phe) at 237 
the N-terminus, and/or Pro/Ala at position 2, and/or Pro at the C-terminus of the peptide 238 
(Nongonierma & FitzGerald, 2013c, 2014a; Nongonierma & FitzGerald, 2016a; Tulipano, 239 
Faggi, Nardone, Cocchi & Caroli, 2015) were searched for within the peptides identified. 240 
2.10 Statistical analysis 241 
A one-way analysis of variance (ANOVA) was used to study differences between mean 242 
values at a significance level of p < 0.05 for the DH and DPP-IV IC50 values. ANOVA was 243 
followed by a Student Newman Keuls post-hoc test for multiple means comparison (p < 0.05) 244 
which was conducted with SPPS (version 22, SPSS Inc., Chicago, IL, USA). 245 
A one-sample Student test with a significance of p < 0.05 was used to test the lack of 246 
significant difference between the experimentally determined and predicted (using the MLR) 247 
DPP-IV IC50 values of the optimised hydrolysate (H16). 248 
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3 Results 249 
3.1 DPP-IV inhibitory and physicochemical properties of the MPI hydrolysates 250 
generated within the experimental design 251 
The reproducibility, in terms of hydrolysate generation, can be seen with the results of the 252 
independent triplicate hydrolysates produced using the central point experimental conditions 253 
(H8A, H8B and H8C). No significant differences (p > 0.05) were observed in terms of their 254 
DH or DPP-IV IC50 values (Table 1). In addition, these three hydrolysates displayed similar 255 
molecular mass distribution profiles (Fig. 1A). 256 
The DPP-IV IC50 values determined for the hydrolysates (H1-H15) generated within the DOE 257 
are reported in Table 1. These varied between 0.60 ± 0.06 (H4) and 2.14 ± 0.21
 
mg mL
-1
 258 
(H14). Hydrolysates generated at temperatures  50C generally displayed the lowest DPP-259 
IV IC50 values. For the other parameters (time and E:S), no clear trend could be seen. 260 
Along with differences in their bioactive properties, dissimilarities in the physicochemical 261 
properties of the hydrolysates were also seen. Their DH values ranged from 3.4 ± 0.6 (H11) 262 
to 11.8 ± 0.7 (H4) or 11.8 ± 1.1% (H8A, Table 1). Differences in the molecular mass 263 
distribution (Fig. 1A) and peptide profiles (data not shown) were also evident. All 264 
hydrolysates still contained some intact proteins (material > 10 kDa), in particular 265 
hydrolysates H11-H15 which were among the less hydrolysed samples. 266 
3.2 Effect of the experimental design parameters on the DPP-IV inhibitory properties 267 
of the MPI hydrolysates 268 
A MLR was used to correlate the parameters of the DOE to the DPP-IV IC50 values of the 269 
resultant hydrolysate (Table 2). The complete model was statistically significant with a p 270 
value of 0.000905 and an R
2
 of 0.95. However, the p value (< 0.05) for the lack of fit 271 
  13 
indicated that the model did not fit well with the experimental data. For this reason, the most 272 
significant parameters (T and t), their binary interactions (T
2
 and t
2
) and the t×E:S interaction 273 
were taken into account to build the simplified model. 274 
In the simplified model, a significant effect (p < 0.05) of T, t, T
2
, t
2
 and t×E:S was also found 275 
(Table 2). The p value (> 0.05) for the lack of fit indicated that the simplified model better 276 
fitted the experimental data. For the main parameters of the DOE, the highest coefficient was 277 
that of temperature (0.34, Table 2). Its positive value indicated that a decrease in temperature 278 
would yield a decrease in the DPP-IV IC50 value (more potent DPP-IV inhibitory 279 
hydrolysate). This effect of temperature decrease in lowering the DPP-IV IC50 value could be 280 
visualised on the RSM curves (Fig. 1B and 1D). The negative value for the coefficient 281 
associated with time (-0.13, Table 2) indicated a reduction in DPP-IV IC50 value as 282 
incubation time increased. However, the effect of time on DPP-IV IC50 value is less than that 283 
of the temperature (Fig. 1B and 1C). The significance of the binary interactions T
2
 and t
2
 284 
suggests the existence of an optimum temperature and time for the generation of a DPP-IV 285 
inhibitory hydrolysate within the boundaries of the DOE. In agreement with the lack of 286 
statistical significance for the E:S (p > 0.05, Table 2), this parameter, minimally modified the 287 
DPP-IV IC50 value (Fig. 1C and 1D). 288 
3.3 Optimisation of the release of DPP-IV inhibitory peptides during enzymatic 289 
hydrolysis of MPI 290 
The RSM allowed prediction of the optimum temperature, time and E:S yielding the most 291 
potent DPP-IV inhibitory hydrolysate within the boundaries of the DOE. It was predicted that 292 
an hydrolysate generated at 46 (-0.4)C, 240 (+1) min and 0.5% (-1) E:S would yield the 293 
lowest DPP-IV IC50 value, which was projected to be 0.43 mg mL
-1
. The observed DPP-IV 294 
IC50 values of the corresponding hydrolysates generated in triplicate (H16A, H16B and 295 
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H16C) are reported in Table 1. These three hydrolysates yielded similar (p > 0.05) DPP-IV 296 
IC50 values, with an average of 0.60  0.07 mg mL
-1
. A one-sample Student test was 297 
conducted to compare the experimental to the predicted DPP-IV IC50 value. Although the 298 
DPP-IV IC50 values predicted and experimentally determined were of the same order, 299 
statistically significant differences (p > 0.05) were seen between both values. 300 
3.4 Stability of DPP-IV inhibitory peptides to gastrointestinal enzymes 301 
The stability of the DPP-IV inhibitory hydrolysates to digestive enzymes was studied using 302 
an in vitro SGID protocol. Elution of peptide peaks differed in the RP-UPLC profiles of H4 303 
and H4_CorPP, indicated peptide degradation following SGID (Fig. 2A and 2B). There was 304 
no significant difference in the DPP-IV IC50 values of H4, before and after the two steps of 305 
the SGID process (pepsin followed by Corolase PP digestion, p > 0.05, Table 1). 306 
Intact MPI did not inhibit DPP-IV (IC50 > 2.7 mg mL
-1
). Following pepsin digestion, the 307 
DPP-IV IC50 value was 2.34 ± 0.28 mg mL
-1
. A significant increase in DPP-IV inhibitory 308 
potency (IC50 = 0.65 ± 0.06 mg mL
-1
, p < 0.05) was observed following pepsin and Corolase 309 
PP digestion of MPI (MPI_CorPP). 310 
Interestingly, there was no significant difference between the DPP-IV IC50 values of H4, 311 
H4_pepsin, H4_CorPP and MPI_CorPP (p > 0.05, Table 1). However, large differences in 312 
the peptide profile of these samples were seen (Fig. 2A-C). 313 
3.5 Identification of peptides within MPI hydrolysates 314 
Previously identified DPP-IV inhibitory peptides were found within all four samples (H4, 315 
H16, H4_CorPP and MPI_CorPP) analysed by LC-MS/MS (Table 3). Some of the peptides 316 
identified within the samples had relatively low DPP-IV IC50 values (< 100 µM). For 317 
example, H4 and H16 contained Val-Leu (present within diverse individual milk proteins), 318 
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Trp-Lys (lactoferrin - LF (f268-269)) and Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu-Glu-Ile-319 
Leu (-Lg (f46-57)), with previously reported DPP-IV IC50 values of 74, 41 and 57 µM, 320 
respectively. MPI_CorPP contained a particularly potent DPP-IV inhibitor, Val-Pro-Leu (s1-321 
CN (f167-169)), also known as Diprotin B, displaying a DPP-IV IC50 value of 16 µM. 322 
Interestingly, Val-Leu/Val-Ile was found in all four samples analysed (Table 3). Eight DPP-323 
IV inhibitory peptides were common between H4 and H16, 6 were common between H4 and 324 
H4_CorPP and 9 were common between H4_CorPP and MPI_CorPP. 325 
Numerous sequences containing DPP-IV inhibitory peptide features, i.e., hydrophobic amino 326 
acid (Trp, Leu, Ile or Phe) at the N-terminus, and/or Pro/Ala at position 2, and/or Pro at the 327 
C-terminus of the peptide, were found within the hydrolysates. The peptides identified within 328 
H4 and arising from -CN, the most abundant individual protein in MPI, are summarised in 329 
Table 4. 330 
4 Discussion 331 
Neutrase 0.8L
TM
 generated food protein hydrolysates with DPP-IV inhibitory properties have 332 
mainly been reported using caprine milk (Zhang, Chen, Zuo, Ma, Zhang & Chen, 2016) and 333 
fish proteins (Sila et al., 2015; Zhang, Chen, Chen, Zeng, Ma & Chen, 2016). Neutrase 334 
0.8L
TM
 does not appear to have been used during the generation of bovine milk protein 335 
hydrolysates with DPP-IV inhibitory properties. The effect of incubation temperature on 336 
DPP-IV inhibition by the MPI hydrolysates is possibly linked to the fact that temperature 337 
affects the kinetics of release of the peptides during enzymatic hydrolysis. In addition, as time 338 
proceeds, a higher extent of protein/peptide breakdown is generally observed during 339 
enzymatic hydrolysis. The lack of an effect of the E:S ratio on the DPP-IV inhibitory 340 
properties was not expected. However, this may suggest that an E:S as low as 0.5% is 341 
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sufficient to release the peptides which contribute to the DPP-IV inhibitory properties of the 342 
MPI hydrolysates. 343 
Differences between the predicted and the experimentally determined DPP-IV IC50 value 344 
(0.43 vs. 0.60  0.07 mg mL-1) may arise from the fact that other parameters (e.g., pH, total 345 
solids, product inhibition, etc.) which were not studied herein may play an important role in 346 
the release of DPP-IV inhibitory peptides from MPI. However, the DPP-IV inhibitory 347 
properties of the MPI hydrolysates could not be further improved within the boundaries of the 348 
experimental design. This can be seen by the lack of significant differences in terms of DPP-349 
IV inhibitory potency of selected MPI hydrolysates (H3, H4, H7, H8, H9 and H16, p  0.05, 350 
Table 1). It is possible that all of the potential DPP-IV inhibitory peptides were completely 351 
released from MPI within the selected hydrolysates. These minimum DPP-IV IC50 values 352 
may be related to a substrate (MPI) limiting effect or to a product-type inhibition exerted by 353 
the peptides released during hydrolysis with Neutrase 0.8L
TM
. This may also explain why E:S 354 
had no influence on the DPP-IV IC50 value. However, complete identification and 355 
quantification of the DPP-IV inhibitory peptides within all the MPI hydrolysates would need 356 
to be carried out to confirm this hypothesis. 357 
Neutrase 0.8L
TM
, which was employed herein, is an enzyme preparation derived from 358 
Bacillus amyloliquefaciens. While it has been reported to have a broad cleavage specificity, it 359 
has been suggested that it may particularly hydrolyse peptide bonds at the C-terminal side of 360 
hydrophobic amino acids (Madsen, Ahmt, Otte, Halkier & Qvist, 1997). This is in agreement 361 
with the peptides identified by LC-MS/MS within H4, showing several peptides with a Pro 362 
C-terminus (Table 4). Peptides with a Pro C-terminus have been linked with DPP-IV 363 
inhibitory properties (Nongonierma & FitzGerald, 2013c). The other frequently reported 364 
features of DPP-IV inhibitory peptides, consisting of Trp, Leu, Ile or Phe at the N-terminus, 365 
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and/or Pro/Ala at position 2 (Nongonierma & FitzGerald, 2014a; Nongonierma & FitzGerald, 366 
2016a; Tulipano et al., 2015), were also found in the peptides identified within H4 (Table 4). 367 
Numerous peptides were common between H4 and H4_CorPP, while others were only 368 
present in one of the hydrolysates. This was the case for Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-369 
Leu-Glu-Ile-Leu, which was further degraded during SGID into shorter fragments such as 370 
Leu-Lys-Pro-Thr-Pro-Glu-Gly-Asp-Leu (-Lg (f46-54)) and Leu-Lys-Pro-Thr-Pro-Glu-Gly-371 
Asp-Leu-Glu (-Lg (f46-55)) which still displayed high DPP-IV inhibitory properties (DPP-372 
IV IC50 values of 45 and 42 µM, respectively (Lacroix & Li-Chan, 2014)). There is a need to 373 
specifically quantify DPP-IV inhibitory peptides within H4 and H4_CorPP in order to better 374 
understand the stability of peptides to SGID. However, this was outside the scope of the 375 
present study. 376 
While MPI_CorPP and H4_CorPP had a similar DPP-IV IC50 value, their peptide 377 
composition was quite different (Table 3). However, particularly potent peptides such as Val-378 
Pro-Leu (s1-CN (f167-169), DPP-IV IC50 = 16 µM (Umezawa, Aoyagi, Ogawa, Naganawa, 379 
Hamada & Takeuchi, 1984)) and Ile-Asn-Asn-Gln-Phe-Leu-Pro-Tyr-Pro-Tyr (κ-CN (f51-60), 380 
DPP-IV IC50 = 40 µM (Zhang, Chen, Ma & Chen, 2015)) were only detected within 381 
MPI_CorPP. A fully annotated representative MS/MS fragmentation spectrum for Ile-Asn-382 
Asn-Gln-Phe-Leu-Pro-Tyr-Pro-Tyr is shown in Supplementary Fig. S1. In order to assess if 383 
there is a benefit to prehydrolyse MPI prior to its ingestion, in vivo studies need to be 384 
performed to better understand the stability, bioavailability and efficacy of the peptides 385 
released from H4 and MPI during gastrointestinal digestion. 386 
The LC-MS/MS results, showing previously reported DPP-IV inhibitory peptides (Table 3) 387 
and peptides having DPP-IV inhibitory features (Table 4), clearly indicate the contribution of 388 
both whey and CN-derived peptides to the overall DPP-IV inhibitory properties of the MPI 389 
hydrolysates. Binary peptide mixtures have previously been used to demonstrate the 390 
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existence of additive and antagonistic effects between DPP-IV inhibitory peptides 391 
(Nongonierma & FitzGerald, 2015b). In addition, numerous peptides within H4 had the 392 
structure of preferred DPP-IV substrates, presenting Pro or Ala residues at the penultimate 393 
position. Such peptides may be able to inhibit DPP-IV through a substrate-type inhibition 394 
mechanism (Nongonierma & FitzGerald, 2014b). Besides known DPP-IV inhibitory peptides, 395 
several of the peptides identified within the hydrolysates, which have not been assessed for 396 
their bioactivity, are likely to contribute to the overall DPP-IV inhibitory properties observed. 397 
Further evaluation of these peptides is required to understand their contribution to the overall 398 
DPP-IV inhibitory properties of MPI hydrolysates. 399 
The MPI hydrolysates generated herein were compared to other milk protein hydrolysates 400 
which DPP-IV inhibitory potency values were obtained using the same assay. The DPP-IV 401 
IC50 values of other relatively potent milk protein-derived hydrolysates varied between 0.88 402 
to 1.43 mg mL
-1
 for sodium caseinate and whey protein isolate hydrolysates, respectively 403 
(Nongonierma & FitzGerald, 2013a). DPP-IV IC50 values ranging from 0.68 to 1.59 mg mL
-1
 404 
have been reported for tryptic MPI hydrolysates (Nongonierma et al., 2017). The low DPP-IV 405 
IC50 values reported herein (Table 1) showed the potential of MPI hydrolysates obtained with 406 
Neutrase 0.8L
TM 
to yield relatively potent inhibition of DPP-IV. 407 
The in vivo antidiabetic evaluation of DPP-IV inhibitory milk protein-derived peptides has 408 
been reported in three small animal studies (Hsieh et al., 2016; Uchida, Ohshiba & Mogami, 409 
2011; Uenishi, Kabuki, Seto, Serizawa & Nakajima, 2012). These studies showed a 410 
significant reduction of serum glucose following a single administration of the hydrolysates. 411 
The mechanism of action highlighting the positive role of milk protein hydrolysate 412 
administration on a reduction of plasma DPP-IV activity was however only demonstrated in 413 
the study of Hsieh et al. (2016). There was a 21.4 to 22.8% reduction of DPP-IV activity in 414 
the plasma of streptozotocin-induced diabetic rats following administration of a bromelain 415 
  19 
CN digest (250-500 mg kg
-1
 body weight). The MPI hydrolysates herein may have potential 416 
as antidiabetic food-grade ingredients. Additional studies are required to verify their in vivo 417 
effects. 418 
5 Conclusions 419 
The in vitro DPP-IV inhibitory potential of bovine MPI hydrolysed with Neutrase 0.8L
TM
 420 
was studied. Within the boundaries of the DOE used, it was shown that temperature and time 421 
had an effect (p < 0.05), while E:S had no effect (p > 0.05) on DPP-IV IC50 values. The MLR 422 
model developed herein did not allow prediction of the optimum conditions for the release of 423 
DPP-IV inhibitory peptides from MPI, however, it did yield a potent hydrolysate (H16). 424 
Several peptides were identified by LC-MS/MS within selected hydrolysates. Some of these 425 
sequences were previously reported as DPP-IV inhibitors or to possess structural features of 426 
DPP-IV inhibitory peptides. Additional studies involving the utilisation of different enzyme 427 
preparations or hydrolytic conditions may allow further improvement in the release of DPP-428 
IV inhibitory peptides from MPI. 429 
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Table 1. Degree of hydrolysis (DH) and dipeptidyl peptidase IV (DPP-IV) half maximal inhibitory concentration (IC50) of the milk protein 567 
isolate (MPI) hydrolysates. 568 
Hydrolysate Variable levels
§
 DH
§§
 
(%) 
DPP-IV IC50
§§,†
 
(mg mL
-1
) 
Temperature (°C) Time (min) E:S (%) 
H1 40 (-1) 60 (-1) 1.0 (-1) 5.8 ± 1.0
fg 1.40 ± 0.12
e
 
H2 40 (-1) 60 (-1) 2.0 (+1) 7.8 ± 1.2
de 0.93 ± 0.07
cd
 
H3 40 (-1) 150 (0) 1.5 (0) 9.9± 0.6
bc
 0.62 ± 0.09
a
 
H4 40 (-1) 240 (+1) 1.0 (-1) 11.8 ± 0.7
a
 0.60 ± 0.06
a
 
H5 40 (-1) 240 (+1) 2.0 (+1) 11.0 ± 1.2
ab 1.05 ± 0.21
d
 
H6 50 (0) 60 (-1) 1.5 (0) 8.5 ± 0.8
de 0.87 ± 0.14
bcd
 
H7 50 (0) 150 (0) 1.0 (-1) 8.8 ± 1.3
cd 0.70 ± 0.13
ab
 
H8A 50 (0) 150 (0) 1.5 (0) 11.8 ± 1.1
a 0.69 ± 0.14
ab
 
H8B 50 (0) 150 (0) 1.5 (0) 11.2 ± 1.1
ab
 0.78 ± 0.27
ab
 
H8C 50 (0) 150 (0) 1.5 (0) 10.8 ± 0.1
ab 0.70 ± 0.16
ab
 
H9 50 (0) 150 (0) 2.5 (+1) 10.9 ± 0.7
ab 0.73± 0.09
abc
 
H10 50 (0) 240 (+1) 1.5 (0) 11.4 ± 1.0
a 0.92 ± 0.16
cd
 
H11 60 (+1) 60 (-1) 1.0 (-1) 3.4 ± 0.6
h 2.07 ± 0.34
g
 
H12 60 (+1) 60 (-1) 2.0 (+1) 6.5 ± 0.7
f 1.45 ± 0.19
e
 
H13 60 (+1) 150 (0) 1.5 (0) 6.4 ± 0.7
f 1.63 ± 0.15
f
 
H14 60 (+1) 240 (+1) 1.0 (-1) 5.0 ± 0.4
g 2.14 ± 0.21
g
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H15 60 (+1) 240 (+1) 2.0 (+1) 7.6 ± 1.8
e 1.66 ± 0.13
f
 
H16A 46 (-0.4) 240 (+1) 1.0 (-1) nd 0.66 ± 0.05
ab
 
H16B 46 (-0.4) 240 (+1) 1.0 (-1) nd 0.56 ± 0.05
a
 
H16C 46 (-0.4) 240 (+1) 1.0 (-1) nd 0.55 ± 0.06
a
 
H4_pepsin - - - nd 0.72 ± 0.06
abc 
H4_CorPP - - - nd 0.58 ± 0.09
a 
MPI_pepsin - - - nd 2.34 ± 0.28
h 
MPI_CorPP - - - nd 0.65 ± 0.06
ab 
§
The z-centred values for each variable of the experimental design are provided in brackets. 569 
§§
Mean  SD (n=3). Within the same column, values with different superscript letters are significantly different (p < 0.05); nd: not determined. 570 
†
IC50: concentration inducing 50% inhibition of DPP-IV, expressed in mg protein equivalent per mL (mg mL
-1
). The IC50 value of the positive 571 
control Ile-Pro-Ile was 2.91 ± 0.28 µM. 572 
573 
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Table 2. Coefficients of the multilinear regression (MLR) model as described in Equation 2. The complete model correlates the dipeptidyl 574 
peptidase IV (DPP-IV) half maximal inhibitory concentration (IC50) of the milk protein isolate (MPI) hydrolysates to the parameters of the 575 
design of experiment (DOE) and their interactions. The simplified model correlates DPP-IV IC50 values to the main parameters of the DOE and 576 
interactions having a p-value  0.2. 577 
 Parameters of the model
§ 
Coefficients Estimate value Standard Error t value p
§§ 
Complete model Intercept β0 0.72 0.06 11.25 9.80E-06 
 T β1 0.34 0.05 7.22 1.75E-04 
 t β2 -0.14 0.05 -2.87 0.02 
 ES β3 -0.02 0.05 -0.44 0.68 
 T² β4 0.42 0.09 4.65 0.02 E-01 
 t² β5 0.15 0.09 1.60 0.15 
 ES² β6 -0.02 E-01 0.09 -0.02 0.98 
 T×t β7 0.01 0.05 0.18 0.86 
 T×ES β8 -0.05 0.05 -0.94 0.38 
 t×ES β9 0.25 0.05 4.80 0.02 E-01 
 Root mean squared error: 0.149; R
2
: 0.95; p-value model = 0.000905; p-value lack of fit = 0.044 
Simplified model Intercept β0 0.72 0.05 13.11 1.26E-07 
 T β1 0.34 0.04 8.10 1.05E-05 
 t β2 -0.13 0.04 -3.22 0.09 E-01 
 ES β3 -0.02 0.04 -0.49 0.63 
 T² β4 0.42 0.08 5.54 2.47E-04 
 t² β5 0.14 0.08 1.90 3.05E-04 
 t×ES β6 0.25 0.05 5.39 3.05E-04 
 Root mean squared error: 0.132; R
2
: 0.94, p-value model = 0.000011; p-value lack of fit= 0.062 
§
T: temperature; t: time and ES: enzyme to substrate ratio. 578 
§§
Coefficients of parameters
 
having a p < 0.05 are significantly different from 0. 579 
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Table 3. Peptides identified by liquid chromatography tandem mass spectrometry (LC-MS/MS) within H4 before and after (H4_CorPP) simulated 580 
gastrointestinal digestion (SGID), the SGID of milk protein isolate (MPI_CorPP) and H16, which have previously been reported in the literature for their 581 
dipeptidyl peptidase IV (DPP-IV) inhibitory properties. 582 
Peptide sequence
§
 Fragment
§§
 Identified in
†
 DPP-IV IC50 
value (µM)
‡ 
Reference 
H4 H4_CorPP MPI_CorPP H16 
FF diverse     547 
(Neves, Harnedy, O’Keeffe & FitzGerald, 
2017) 
FL diverse     400 (Nongonierma & FitzGerald, 2013a) 
HL diverse nd  nd nd 143 (Nongonierma & FitzGerald, 2013a) 
INNQFLPYPY κ-CN (f51-60) nd nd  nd 40 (Zhang et al., 2015) 
LKPTPEGDL -Lg (f46-54) nd  nd nd 45 (Lacroix & Li-Chan, 2014) 
LKPTPEGDLE -Lg (f46-55) nd   nd 42 (Lacroix & Li-Chan, 2014) 
LKPTPEGDLEIL -Lg (f46-57)  nd   57 (Lacroix & Li-Chan, 2014) 
LL diverse     192 
(Connolly, O'Keeffe, Nongonierma, Piggott 
& FitzGerald, 2017) 
TPEVDDEALEK -Lg (f125-135) nd   nd 320 
(Silveira, Martínez-Maqueda, Recio & 
Hernández-Ledesma, 2013) 
VL(I) diverse     74 
(Lan, Ito, Ohno, Motoyama, Ito & 
Kawarasaki, 2015) 
VLGP -CN (f197-1200),   nd  580 (Nongonierma & FitzGerald, 2013c) 
VLVLDTDYK -Lg (f92-100) nd   nd 424 (Silveira et al., 2013) 
VPL s1-CN (f167-169) nd nd  nd 16 (Umezawa et al., 1984) 
WK LF (f268-269)  nd nd  41 (Nongonierma & FitzGerald, 2013d) 
WQ 
LF (f22-23), κ-CN 
(f76-77) 
    120 (Nongonierma & FitzGerald, 2013d) 
YPVEPF -CN (f114-119) nd   nd 125 (Nongonierma & FitzGerald, 2016b) 
§
Peptide sequences abbreviated with the one letter amino acid code 583 
§§
CN : casein ; LF : lactoferrin; -Lg: -lactoglobulin; diverse: sequence identified in > 2 individual milk proteins. 584 
. 585 
  31 
† : DPP-IV inhibitory peptides detected in the different samples; nd: not detected. 586 
‡
DPP-IV IC50 : dipeptidyl peptidase IV half maximal inhibitory concentration as reported at the first mention in the literature. 587 
  32 
Table 4. Peptide sequences arising from -casein (-CN) identified within H4, which display features of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides 588 
(Trp (W1), , Ile (I1), Leu (L1) or Phe (F1) at the N-terminus and/or Pro (P2)/Ala (A2) at position 2 and/or Pro at the C-terminus (P-term)). 589 
Peptide sequence
§
 Fragment number DPP-IV inhibitory peptide features
†
 
W1 I1 L1 F1 P2 A2 P-term 
AM(+15.99)APKHKEMPFPKYPVEP (f101-118)       
AMAPKHK(+15.99*)EMPFPKYP (f101-115) 
      

AMAPKHKEMPFPKYP (f101-115) 
      

AMAPKHKEMPFPKYPVEP (f101-118) 
      

AVPYPQRDM(+15.99)P (f177-186) 
      

AVPYPQRDMP (f177-186) 
      

EMPFPKYP (f108-115) 
      

EMPFPKYPVEP (f108-118) 
      

FAQTQ (f52-56)       
FAQTQS (f52-57)       
FL (f87-88), (f190-191)       
FLL (f190-192)       
FQ (f33-34)       
FQSEEQQQTEDELQDKIHP (f33-51)       
FTESQS (f119-124)       
HKEMPFPKYP (f106-115) 
      

HKEMPFPKYPVEP (f106-118) 
      

IEKFQS(+79.97)EEQQQTEDELQDK (f30-48)       
IPPLTQTPVVVPPF (f74-87)       
IVES(+79.97)LS(+79.97)SSEESITR (f10-25)       
KAVPYPQRDMP (f176-186)       
L(I)E (f3-4)       
  33 
LEE (f3-5)       
LGP (f198-200)       
LGPVRGPFP (f198-206)       
LGPVRGPFPI (f198-207)       
LHLPLP (f133-138)       
LHLPLPL (f133-139)       
LL (f139-140), (f191-192)       
LLQ (f139-141)       
LLQS (f139-142)       
L(I)N (f6-7)      
LNVPGE (f6-11)       
L(I)Q 
(f45-46), (f88-89), (f140-
141) 
     
LQPEVM(+15.99)G (f88-94)       
LQPEVMG (f88-94)       
LS 
(f88-94), (f163-164), 
(f165-166) 
      
LSQ/LQS (f165-167)       
LSQSK (f165-169)       
LSQSKVLPVPQ (f165-175)       
LSQSKVLPVPQK (f165-176)       
L(I)T 
(f77-78), (f125-126), 
(f127-128) 
     
LTDVEN (f127-132)       
LTL (f125-127)       
LTQTP (f77-81)       
LTQTPVVVPPF (f77-87)       
LTQTPVVVPPF(+21.98) (f77-87)       
LV (f58-59)       
  34 
LVYPFPGPIPN (f58-68)       
LVYPFPGPIPNSLPQNIPP (f58-76)       
LVYPFPGPIPNSLPQNIPPLTQTPVVVPPF (f58-87)       
LY (f192-193)       
LYQEPVLGP (f192-200)       
LYQEPVLGPVRGPFP (f192-206)       
LYQEPVLGPVRGPFPIIV (f192-209)       
MAPKHKEMPFPKYP (f102-115) 
    
 
MAPKHKEMPFPKYPVEP (f102-118) 
    
 
SLPQNIPP (f69-76) 
      

SLPQNIPPLTQTP (f69-81) 
      

VEP (f116-118) 
      

VLGP (f197-200) 
      

VLGPVRGPFP (f197-206) 
      

VRGPFP (f201-206) 
      

VYPFPGP (f59-65) 
      

VYPFPGPIPNSLPQNIPP (f59-76) 
      

VYPFPGPIPNSLPQNIPPLTQTP (f59-81) 
      

WM(+15.99)HQPHQPLPPT (f143-154) 
      
WMHQPHQPLPPT (f143-154)       
§
Peptide sequences abbreviated with the one letter amino acid code; Post translational modifications as oxidation (+15.99), hydroxylation (+15.99*), 590 
phosphorylation (+79.97) and sodium adduct: (+21.98).  591 
†✓: DPP-IV inhibitory feature present within the peptide sequence. 592 
 593 
 594 
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Figure captions 595 
 596 
Figure 1. (A) Molecular mass distribution of the 15 milk protein isolate (MPI) hydrolysates 597 
generated within the experimental design (H1-H15) and the simulated gastrointestinal 598 
digestion (SGID) samples of H4 and MPI. Pepsin: sample digested with pepsin; CorPP: 599 
sample digested with pepsin then Corolase PP. Response surface methodology (RSM) curves 600 
of the dipeptidyl peptidase IV (DPP-IV) half maximal concentration (IC50) as a function of 601 
(B) time and temperature (Temp), (C) time and enzyme to substrate ratio (ES) and (D) Temp 602 
and ES. The RSM curves were constructed using the optimised model at the central condition 603 
(0) of the parameter which is not varied on each figure panel (B, C and D). 604 
 605 
Figure 2. Reverse phase ultra-performance liquid chromatography (RP-UPLC) profile of the 606 
milk protein isolate (MPI) hydrolysates (A) H4, (B) H4_CorPP, the simulated gastrointestinal 607 
digest (SGID) of H4 and (C) MPI_CorPP, the SGID of MPI. 608 
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Supplementary Figure S1. The fully annotated MS/MS fragmentation spectrum for Ile-Asn-Asn-Gln-Phe-
Leu-Pro-Tyr-Pro-Tyr. 
 
 
 
 
 
